Physician profile
Ashton Taylor Hilton
NPI 1215236112
$9,917.26
in general payments reported to CMS, 2019-2025
35 companies · $2,400 in 2025
The $2,400 reported for 2025 was more than what a typical Clinical & Laboratory Dermatological Immunology provider received nationally (typical 2025 total: $1,130).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $698 · 2020: $601 · 2021: $987 · 2022: $1,369 · 2023: $1,960 · 2024: $1,900 · 2025: $2,400.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,864 · Education: $397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,863.87 |
| Education | $397.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,511.19 | 2019-2025 | |
| Ucb, INC. | $950.23 | 2019-2025 | Bimzelx, Cimzia |
| Janssen Biotech, INC. | $884.10 | 2020-2025 | Tremfya |
| Genzyme Corporation | $766.48 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $685.73 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $662.79 | 2019-2024 | |
| Pfizer INC. | $532.55 | 2019-2025 | |
| Amgen INC. | $507.61 | 2020-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $444.48 | 2020-2025 | Ilumya, Winlevi, Absorica Ld |
| Lilly USA, LLC | $371.15 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Incyte Corporation | $358.52 | 2021-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $308.48 | 2019-2024 | Arazlo, Jublia, Cabtreo |
| E.R. Squibb & Sons, L.L.C. | $308.45 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $277.44 | 2021-2025 | Dupixent |
| Galderma Laboratories, L.P. | $227.60 | 2019-2025 | Nemluvio, Dysport, Aklief |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $122.79 | 2022-2024 | Vtama |
| Arcutis Biotherapeutics, INC. | $122.56 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $108.25 | 2020-2024 | Adbry |
| Organon LLC | $97.84 | 2025 | Vtama |
| Journey Medical Corporation | $97.60 | 2022-2023 | |
| Botanix Sb INC | $87.96 | 2025 | Sofdra |
| Allergan, INC. | $66.12 | 2019-2021 | |
| Vyne Pharmaceuticals INC. | $64.35 | 2020 | |
| Almirall LLC | $63.07 | 2021-2024 | Klisyri |
| Epi Health, LLC | $55.72 | 2019-2022 | |
| Medimetriks Pharmaceuticals, INC. | $54.67 | 2022-2024 | Clindacin Etz |
| Dermira, INC. | $26.62 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $26.34 | 2025 | Tremfya |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.30 | 2023 | Spevigo |
| Merz North America, INC. | $20.12 | 2020 | |
| Verrica Pharmaceuticals INC. | $18.50 | 2025 | Ycanth |
| Mission Pharmacal Company | $18.19 | 2019 | |
| Celgene Corporation | $18.09 | 2019 | |
| Merck Sharp & Dohme LLC | $14.28 | 2019 | |
| Nabriva Therapeutics, Plc | $13.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashton Hilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.